I realize this is nitpicking a minor point in your comment, but I don't agree with your characterization of RCTs in medical research as being primarily constrained by laws and regulations. Any time I've discussed research on human subjects with doctors doing that research, the discussion of what is and is not an acceptable experiment has always been primarily driven by the risks of harm to the people involved in the study. Any time the law comes up, it's usually because the law requires an RCT in a specific setting, as opposed to preventing it (e.g. drug trials). (Of course in the setting of starting a company based on some medical product, the situation may be quite different.)
Biologists, if not data scientists, are used to considering indirect evidence for causality. It's why we sometimes accept studies performed in other organisms as evidence for biology in humans; it's why we sometimes accept research performed on post-mortem human tissue as being representative of the biology of living humans; to name but a few examples. A big part of a compelling high-impact biology (or bioinformatics) paper is often the innovative ways that one comes up to show causality when a direct RCT is not feasible, and papers are frequently rejected because they don't to the follow-up experiments required to show causality.
That's a very fair point. I didn't mean to suggest that harm to the patients or subjects was not the overriding factor, nor that bio, pharma, and other medical fields never do RCTs.
But there are a slew of laws and requirements around _how_ to run an RCT across the world of bio-related work, esp as it becomes a product. From marketing to manufacture to packaging, there are strict limits around where variation is allowed, at least anything involving the FDA in the US. (Some would say too many regs, others say not enough).
And in those cases, having a wider collection of ways to impute cause would be great.
Biologists, if not data scientists, are used to considering indirect evidence for causality. It's why we sometimes accept studies performed in other organisms as evidence for biology in humans; it's why we sometimes accept research performed on post-mortem human tissue as being representative of the biology of living humans; to name but a few examples. A big part of a compelling high-impact biology (or bioinformatics) paper is often the innovative ways that one comes up to show causality when a direct RCT is not feasible, and papers are frequently rejected because they don't to the follow-up experiments required to show causality.